Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Jul;9(7):1977-84.
doi: 10.1158/1535-7163.MCT-10-0141. Epub 2010 Jun 22.

PS-341 and histone deacetylase inhibitor synergistically induce apoptosis in head and neck squamous cell carcinoma cells

Affiliations

PS-341 and histone deacetylase inhibitor synergistically induce apoptosis in head and neck squamous cell carcinoma cells

Jinkoo Kim et al. Mol Cancer Ther. 2010 Jul.

Abstract

Proteasome inhibitor PS-341 (also known as bortezomib) and histone deacetylase (HDAC) inhibitors have emerged as novel therapeutic agents for a variety of malignancies. In this study, we examined whether PS-341 and the HDAC inhibitor trichostatin A (TSA) induced apoptosis in head and neck squamous cell carcinoma (HNSCC), a common and lethal malignancy. We found that, although TSA treatment alone did not induce apoptosis in HNSCC cells, it significantly enhanced PS-341-induced apoptosis in HNSCC cells in vitro. Consistently, TSA significantly improved PS-341-mediated inhibition of HNSCC tumor growth in nude mice. Mechanistically, we found that TSA increased PS-341-induced Noxa expression and caspase activation in HNSCC cells. The knockdown of Noxa significantly reduced apoptosis induced by cotreatment of PS-341 and TSA. Taken together, our results provide new insight into the mechanisms of synergistic antitumor activity of the PS-341 and HDAC inhibitor regimen, offering a new therapeutic strategy for HNSCC patients.

PubMed Disclaimer

Conflict of interest statement

No potential conflicts of interest were disclosed.

Figures

Figure 1
Figure 1
TSA enhances PS-341-mediated apoptosis in HNSCC cells. A, TSA enhanced the cell death induced by PS-341 in UMSCC1 cells. Cell viability was determined by the trypan blue exclusion assay. The assays were performed with triplicate samples, and the results are representative of three independent experiments (**P < 0.01). Error bars depict standard deviation. B, C and D, TSA enhanced PS-341-induced cell death in UMSCC23 (B), UMSCC9 (C), and FaDu (D). **P < 0.01. E, TSA enhanced PS-341-mediated apoptosis in HNSCC cells. UMSCC-1 and UMSCC-23 cells were treated with PS-341 alone, TSA alone, and PS-341 and TSA together for 24 h. After treatment, the detached and attached cells were pooled, and genomic DNA was extracted with phenol-chloroform-isoamyl alcohol and genomic DNAs were separated on a 1.5% agarose gel. M, 1 kb DNA ladder. F. TSA enhanced PS-341-mediated inhibition of HNSCC tumor growth in vivo. UMSCC1 cells were subcutaneously inoculated into nude mice for one week and then treated with vehicle control, TSA, PS-341, or PS-341 plus TSA for three weeks. Tumor size was daily measured for indicated days. *P < 0.05 (n = 5; PS-341 plus TSA vs PS-341 or TSA).
Figure 2
Figure 2
TSA enhances caspase activation induced by PS-341 in HNSCC cells. A, TSA enhanced caspase activation induced by PS-341 in UMSCC1 cells. UMSCC-1 cells were treated with PS-341 alone, TSA alone, or PS-341 and TSA together for 0, 4, 8, 12, or 16 h. Whole cell extracts were prepared, and 50- µg aliquots of proteins were probed with anti-caspase-3, anti-caspase-7, and anti-caspase-9 antibodies. For the loading control, the membrane was stripped and re-probed with monoclonal antibodies against α-tubulin. B, TSA enhanced caspase activation induced by PS-341 in UMSCC23 cells. P+T, PS-341 + TSA.
Figure 3
Figure 3
TSA does not modulate PS-341-induced ER stress in HNSCC cells. A and B, TSA did not affect the expression of ATF4 and GADD34 induced by PS-341 in HNSCC cells. Whole cell extracts were prepared, and 50- µg aliquots of proteins were examined with polyclonal antibodies against ATF-4 and GADD-34. For loading control, the membranes were stripped and re-probed with monoclonal antibodies against α-tubulin. P + T, PS-341 + TSA.
Figure 4
Figure 4
Promoting histone H3 acetylation in HNSCC cells by TSA. A and B, TSA induced hyperacetylation of histone H3 in HNSCC cells. UMSCC1 and UMSCC23 cells were treated with PS-341 alone (0.5 µM), TSA alone (300 nM), or PS-341 and TSA together for indicated times. 50- µg aliquots of proteins were probed with anti-acetyl-histone H3 antibodies (1:1000). For a loading control, the membrane were stripped and re-probed with monoclonal antibodies against α-tubulin.
Figure 5
Figure 5
TSA enhances PS-341-induced Noxa expression. A, TSA enhanced PS-341-induced Noxa expression as determined by Western blot analysis. Cells were treated with PS-341 alone, TSA alone, or PS-341 and TSA together for indicated time periods. 50-µg aliquots of cell lysates were probed with anti-Noxa, anti-Puma, or anti-Bax antibodies. α-Tubulin was utilized as an internal control. B, TSA enhanced Noxa mRNA expression induced by PS-341. Total RNA was isolated and determined by Real-time PCR.
Figure 6
Figure 6
Noxa plays a critical role in TSA- and PS-341-induced apoptosis in HNSCC cells. A, Knock-down of Noxa in UMSCC1 and UMSCC23 cells. SCC cells were transfected with Noxa siRNA or control luciferase siRNA using fugene. Cell lysates were probed with anti-Noxa antibodies. α-Tubulin was utilized as an internal control. B, Knock-down of Noxa inhibited PS-341 and TSA-induced apoptosis. Cells were transfected with siRNA as described in A. 48 h after transfection, cells were treated with PS-341 alone or PS-341 and TSA together for 16 h. Cell viability was determined by Trypan blue exclusion assay. The results are average values from three independent experiments (** P < 0.01).

References

    1. Lemaire F, Millon R, Wasylyk B, et al. Differential expression profiling of head and neck squamous cell carcinoma (HNSCC) Br J Cancer. 2003;89:1940–1949. - PMC - PubMed
    1. Pisani P, Bray F, Parkin DM. Estimates of the world-wide prevalence of cancer for 25 sites in the adult population. Int J Cancer. 2002;97:72–81. - PubMed
    1. Pisani P, Bray F, Ferlay J, Parkin DM. Global Cancer Statistics, 2002. CA Cancer J Clin. 2005;55:74–108. - PubMed
    1. Fribley A, Evenchik B, Wang CY, et al. Proteasome inhibitor PS-341 induces apoptosis in cisplatin-resistant squamous cell carcinoma cells by induction of Noxa. J Biol Chem. 2006;281:31440–31447. - PubMed
    1. Fribley A, Zeng Q, Wang CY. Proteasome inhibitor PS-341 induces apoptosis through induction of endoplasmic reticulum stress-reactive oxygen species in head and neck squamous cell carcinoma cells. Mol Cell Biol. 2004;24 9695-04. - PMC - PubMed

Publication types

MeSH terms